Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

U.S. stocks wavered amid increased volatility on Friday but managed to resurge, as Wall Street was rattled by concerns on the health of regional banks and credit risks while the U.S. government ...

Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of ...

Just one of the so-called Magnificent Seven megacap tech companies is expected to be a top 5 contributor to the S&P 500’s ...

Pharmaceutical stocks gained Wednesday afternoon amid anticipation Pfizer's deal with the Trump administration could lead to ...

Eli Lilly (LLY) reached $855.35 at the closing of the latest trading day, reflecting a +1.14% change compared to its last close.

The Dow, S&P 500 and Nasdaq all rose this week, as investors shook off concerns about bad loans as well as trade tensions ...

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Fundamentally, Eli Lilly represents a juggernaut in medical innovations. Recently, the company has taken a leadership role in ...

These two stocks have lagged the S&P 500 over the past year. Coca-Cola has raised its dividend for 63 straight years. Eli Lilly appeals to growth and income investors. These two underperforming stocks ...

Key Points Chesapeake sold 9,875 Eli Lilly and Company shares; estimated trade value of approximately $7.68 million, based on the average price for Q2 2025 Transaction represented 6.9% of fund AUM.